{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:58:11Z","timestamp":1788501491732,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.iac.2024.07.008","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T21:39:00Z","timestamp":1724362740000},"page":"751-763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Biologics in Asthma"],"prefix":"10.1016","volume":"44","author":[{"given":"Brinda","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Adrish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Njira L.","family":"Lugogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.iac.2024.07.008_bib1","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202311-2192OC","article-title":"Exploring definitions and predictors of severe asthma clinical remission post-biologic in adults","author":"Perez-de-Llano","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.iac.2024.07.008_bib2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12931-024-02812-3","article-title":"Barriers to clinical remission in severe asthma","volume":"25","author":"Farinha","year":"2024","journal-title":"Respir Res"},{"key":"10.1016\/j.iac.2024.07.008_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0144-2022","article-title":"Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD","author":"Calderon","year":"2023","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.iac.2024.07.008_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107847","article-title":"The central role of IL-33\/IL-1RL1 pathway in asthma: From pathogenesis to intervention","author":"Saikumar","year":"2021","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.iac.2024.07.008_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0193-2022","article-title":"Cytokine-targeted therapies for asthma and COPD","author":"Schleich","year":"2023","journal-title":"Eur Respir Rev"},{"issue":"18","key":"10.1016\/j.iac.2024.07.008_bib6","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","article-title":"Efficacy and safety of itepekimab in patients with moderate-to-severe asthma","volume":"385","author":"Wechsler","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.iac.2024.07.008_bib7","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2024.07.008_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-36642-y","article-title":"Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE\/EGFR to reduce inflammation and epithelial dysfunction","author":"England","year":"2023","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.iac.2024.07.008_bib10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/WOX.0b013e31821188e0","article-title":"Interleukin-13 Signaling and Its Role in Asthma","volume":"4","author":"Rael","year":"2011","journal-title":"World Allergy Organization Journal"},{"key":"10.1016\/j.iac.2024.07.008_bib11","doi-asserted-by":"crossref","first-page":"851940","DOI":"10.3389\/fphar.2022.851940","article-title":"Interleukins 4 and 13 in asthma: key pathophysiologic cytokines and druggable molecular targets","volume":"13","author":"Pelaia","year":"2022","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.iac.2024.07.008_bib12","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1055\/s-0042-1743290","article-title":"FeNO in Asthma","volume":"43","author":"Loewenthal","year":"2022","journal-title":"Semin Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.iac.2024.07.008_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics13081428","article-title":"Update on the Role of FeNO in asthma management","volume":"13","author":"Murugesan","year":"2023","journal-title":"Diagnostics"},{"issue":"5","key":"10.1016\/j.iac.2024.07.008_bib14","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jaip.2024.02.007","article-title":"Lebrikizumab in uncontrolled asthma: reanalysis in a well-defined type 2 population","volume":"12","author":"Corren","year":"2024","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"10","key":"10.1016\/j.iac.2024.07.008_bib15","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"18","key":"10.1016\/j.iac.2024.07.008_bib16","article-title":"Severe Asthma and Biological Therapies: Now and the Future","volume":"12","author":"Sardon-Prado","year":"2023","journal-title":"J\u00a0Clin Med"},{"issue":"4","key":"10.1016\/j.iac.2024.07.008_bib17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.anai.2023.11.021","article-title":"Impact of dupilumab across seasons in patients with type 2, uncontrolled, moderate-to-severe asthma","volume":"132","author":"Peters","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.iac.2024.07.008_bib18","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10930-023-10134-4","article-title":"Development of hemagglutinin-neuraminidase homologous peptides as novel promising therapeutic agents against peste des petits ruminants virus","volume":"42","author":"Agrawal","year":"2023","journal-title":"Protein J"},{"issue":"9","key":"10.1016\/j.iac.2024.07.008_bib19","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1080\/02770903.2023.2185895","article-title":"Dupilumab long-term efficacy in patients with non-OCS-dependent asthma with and without evidence of allergic asthma","volume":"60","author":"Sher","year":"2023","journal-title":"J\u00a0Asthma"},{"issue":"1","key":"10.1016\/j.iac.2024.07.008_bib20","doi-asserted-by":"crossref","first-page":"15025","DOI":"10.1038\/nrdp.2015.25","article-title":"Asthma","volume":"1","author":"Holgate","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.iac.2024.07.008_bib21","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2147\/JAA.S275039","article-title":"Targeting TSLP in Asthma","volume":"15","author":"Parnes","year":"2022","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.iac.2024.07.008_bib22","first-page":"A6816","article-title":"Targeting of TSLP and IL-13 by the Novel NANOBODY\u00ae Molecule SAR443765 Reduces FeNO in Asthma Following Single Dose Exposure (abstract)","volume":"207","author":"Deiteren","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.iac.2024.07.008_bib23","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jaci.2021.02.042","article-title":"Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trial","volume":"148","author":"Braithwaite","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2024.07.008_bib24","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.2147\/DDDT.S354291","article-title":"Characterization of selective and potent JAK1 inhibitors intended for the inhaled treatment of asthma","volume":"16","author":"Nilsson","year":"2022","journal-title":"Drug Des Dev Ther"},{"issue":"5","key":"10.1016\/j.iac.2024.07.008_bib25","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.4049\/jimmunol.1202859","article-title":"A\u00a0Restricted Role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors","volume":"191","author":"Sohn","year":"2013","journal-title":"J\u00a0Immunol"},{"issue":"12","key":"10.1016\/j.iac.2024.07.008_bib26","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.bmcl.2019.04.008","article-title":"Discovery of a class of highly potent Janus Kinase 1\/2 (JAK1\/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling","volume":"29","author":"Zak","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"10.1016\/j.iac.2024.07.008_bib27","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1378\/chest.11-1730","article-title":"OX40\/OX40 Ligand Interactions in T-Cell Regulation and Asthma","volume":"141","author":"Kaur","year":"2012","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.iac.2024.07.008_bib28","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1016\/j.jaci.2020.10.037","article-title":"Combination blockade of OX40L and CD30L inhibits allergen-driven memory TH2 cell reactivity and lung inflammation","volume":"147","author":"Gracias","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2024.07.008_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/cea.12235","article-title":"<scp>OX<\/scp> 40L blockade and allergen-induced airway responses in subjects with mild asthma","volume":"44","author":"Gauvreau","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.iac.2024.07.008_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115327","article-title":"A\u00a0panoramic review of IL-6: Structure, pathophysiological roles and inhibitors","author":"Kaur","year":"2020","journal-title":"Bioorg Med Chem"},{"issue":"5","key":"10.1016\/j.iac.2024.07.008_bib32","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1164\/ajrccm.151.5.7735584","article-title":"Circulating interleukin-6 levels in patients with bronchial asthma","volume":"151","author":"Yokoyama","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.iac.2024.07.008_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/thoraxjnl-2020-215266","article-title":"Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19","author":"Khan","year":"2021","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.iac.2024.07.008_bib34","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jaip.2019.02.043","article-title":"Treatment of severe persistent asthma with il-6 receptor blockade HHS public access","volume":"7","author":"Esty","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.iac.2024.07.008_bib35","doi-asserted-by":"crossref","first-page":"e1044","DOI":"10.1002\/cti2.1044","article-title":"Effects of interleukin-6 receptor blockade on allergen-induced airway responses in mild asthmatics","volume":"8","author":"Revez","year":"2019","journal-title":"Clin Transl Immunology"},{"issue":"7","key":"10.1016\/j.iac.2024.07.008_bib36","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S2213-2600(16)30048-0","article-title":"Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts","volume":"4","author":"Peters","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.iac.2024.07.008_bib37","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s40259-020-00430-1","article-title":"Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks","volume":"34","author":"Crisafulli","year":"2020","journal-title":"BioDrugs"},{"issue":"5","key":"10.1016\/j.iac.2024.07.008_bib38","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1164\/ajrccm.160.5.9806170","article-title":"Neutrophilic inflammation in severe persistent asthma","volume":"160","author":"JATAKANON","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.iac.2024.07.008_bib39","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1378\/chest.119.5.1329","article-title":"Heterogeneity of airway inflammation in persistent asthma","volume":"119","author":"Gibson","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.iac.2024.07.008_bib40","article-title":"Pathological roles of neutrophil-mediated inflammation in asthma and its potential for therapy as a target","volume":"2017","author":"Gao","year":"2017","journal-title":"J\u00a0Immunol Res"},{"issue":"11","key":"10.1016\/j.iac.2024.07.008_bib41","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1164\/rccm.201212-2318OC","article-title":"Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma","volume":"188","author":"Busse","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"18","key":"10.1016\/j.iac.2024.07.008_bib42","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1056\/NEJMoa2030880","article-title":"Risankizumab in severe asthma \u2014 a phase 2a, placebo-controlled trial","volume":"385","author":"Brightling","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.iac.2024.07.008_bib43","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s40265-017-0740-2","article-title":"Reslizumab in eosinophilic asthma: a review","volume":"77","author":"Deeks","year":"2017","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.iac.2024.07.008_bib44","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1080\/02770903.2017.1379534","article-title":"Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials","volume":"55","author":"Tian","year":"2018","journal-title":"J\u00a0Asthma"},{"issue":"6","key":"10.1016\/j.iac.2024.07.008_bib45","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/14712598.2019.1610382","article-title":"An evaluation of mepolizumab for the treatment of severe asthma","volume":"19","author":"Morjaria","year":"2019","journal-title":"Expet Opin Biol Ther"},{"issue":"2","key":"10.1016\/j.iac.2024.07.008_bib46","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bcp.15002","article-title":"A\u00a0Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma","volume":"88","author":"Singh","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.iac.2024.07.008_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12111025","article-title":"Pulmonary delivery of biological drugs","volume":"12","author":"Liang","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.iac.2024.07.008_bib48","doi-asserted-by":"crossref","unstructured":"S\u00e9cher T, Heuz\u00e9-Vourc\u2019h N. Pulmonary Delivery of Antibody for the Treatment of Respiratory Diseases. In: Lam J, Kwok PCL, editors. Respiratory Delivery of Biologics, Nucleic Acids, and Vaccines. AAPS Introductions in the Pharmaceutical Sciences, vol 8. Springer, Cham. 2023. https:\/\/doi.org\/10.1007\/978-3-031-47567-2_2.","DOI":"10.1007\/978-3-031-47567-2_2"},{"issue":"1\u20132","key":"10.1016\/j.iac.2024.07.008_bib49","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijpharm.2018.07.054","article-title":"Dosing considerations for inhaled biologics","volume":"549","author":"Ferrati","year":"2018","journal-title":"Int J Pharm"},{"key":"10.1016\/j.iac.2024.07.008_bib50","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-017-0054-z","article-title":"Challenges and future prospects for the delivery of biologics: oral mucosal, pulmonary, and transdermal routes","author":"Morales","year":"2017","journal-title":"AAPS"},{"issue":"1\u20132","key":"10.1016\/j.iac.2024.07.008_bib51","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijpharm.2018.10.029","article-title":"Advanced formulations for intranasal delivery of biologics","volume":"553","author":"Rohrer","year":"2018","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.iac.2024.07.008_bib52","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1208\/s12249-016-0525-z","article-title":"Overview and future potential of buccal mucoadhesive films as drug delivery systems for biologics","volume":"18","author":"Montenegro-Nicolini","year":"2017","journal-title":"AAPS PharmSciTech"},{"issue":"8","key":"10.1016\/j.iac.2024.07.008_bib53","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/17425247.2018.1504017","article-title":"Recent advances in oral delivery of biologics: nanomedicine and physical modes of delivery","volume":"15","author":"Vllasaliu","year":"2018","journal-title":"Expet Opin Drug Deliv"},{"issue":"1\u20132","key":"10.1016\/j.iac.2024.07.008_bib54","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ijpharm.2013.02.031","article-title":"Inhaled proteins: challenges and perspectives","volume":"447","author":"Depreter","year":"2013","journal-title":"Int J Pharm"},{"issue":"4","key":"10.1016\/j.iac.2024.07.008_bib55","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/jam.1998.11.197","article-title":"Safety of inhaled proteins for therapeutic use","volume":"11","author":"Wolff","year":"1998","journal-title":"J\u00a0Aerosol Med"},{"issue":"2\u20133","key":"10.1016\/j.iac.2024.07.008_bib56","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v12.i2-3.20","article-title":"Delivery of biotherapeutics by inhalation aerosol","volume":"12","author":"Niven","year":"1995","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"issue":"2","key":"10.1016\/j.iac.2024.07.008_bib57","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.addr.2008.09.011","article-title":"Extracellular barriers in respiratory gene therapy","volume":"61","author":"Sanders","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.iac.2024.07.008_bib58","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2147\/JAA.S369836","article-title":"Management of uncontrolled asthma: a framework for novel and legacy biologic treatments","volume":"15","author":"Tan","year":"2022","journal-title":"J\u00a0Asthma Allergy"},{"issue":"6428","key":"10.1016\/j.iac.2024.07.008_bib59","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.iac.2024.07.008_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065994","article-title":"Nanobodies: a review of generation, diagnostics and therapeutics","volume":"24","author":"Jin","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.iac.2024.07.008_bib61","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00216-019-01633-4","article-title":"Nanobody: outstanding features for diagnostic and therapeutic applications","volume":"411","author":"Salvador","year":"2019","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.iac.2024.07.008_bib62","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720902904","article-title":"Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura","volume":"11","author":"Hanlon","year":"2020","journal-title":"Ther Adv Hematol"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856124000572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856124000572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T12:39:51Z","timestamp":1728391191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856124000572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0889856124000572"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2024.07.008","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics in Asthma","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2024.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}